Logo

American Heart Association

  1
  0


Final ID: WMP66

Oxygen Extraction Fraction on Baseline MRI Predicts Infarction Growth in Successfully Recanalized Patients

Abstract Body: BACKGROUND:
Despite recent advances in endovascular treatment for acute ischemic stroke (AIS), continued infarct growth and poor functional outcome has been reported in 20-50% of patients despite successful reperfusion. Oxygen extraction fraction (OEF) has shown promise as a method to evaluate ischemic tissue viability and can now be quantified from dynamic-susceptibility-contrast (DSC) perfusion MRI. We aimed to determine the association of OEF alterations on pretreatment DSC perfusion MRI with infarct growth among stroke patients that achieved successful reperfusion.

METHODS:
In this retrospective study, we included patients with anterior circulation LVO, who achieved successful reperfusion (TICI ≥ 2b), and had pretreatment DSC perfusion and posttreatment MRI within 48 hours from reperfusion. DSC perfusion was analyzed using the Cercare Medical Neurosuite (Cercare Medical). OEF values were quantified from the segmented ischemic core (ADC ≤620 ×10-6 mm2/s) and penumbra tissue (Tmax >6 sec) on pretreatment MRI and normalized to the contralateral hemisphere (rOEF). Infarct growth was determined if the final infarct volume was ≥ 10 mL larger than baseline ischemic core volume. The association between rOEF in conjunction with demographic, clinical, other imaging variables and infarct growth were evaluated by univariate and multivariate analysis.

RESULTS:
Among 94 patients who achieved successful reperfusion, 30 (32%) patients had infarct growth ≥ 10 mL. While there was no significant difference in rOEF values measured in the ischemic core between patients with and without infarct growth, the OEF values were significantly (p=0.004) higher in penumbral tissue of patients without infarction growth. ROC analysis showed an AUC: 0.70, sensitivity of 62.1% and specificity of 70.5% for penumbra-rOEF values at threshold of ≥ 1.8. Multivariate logistic regression analysis revealed penumbra-rOEF (p= 0.002) as an independent variable for prediction of infarct growth ≥ 10 mL (p=0.002) with Odds ratio of 0.057 (95%CI: 0.010-0.321).

CONCLUSION:
Infarct growth occured in about 1/3 of patients despite successful recanalization. Low rOEF values in the penumbra tissue could be predictive of infarct growth while elevation of rOEF ≥1.8 could be protective.
  • Asghariahmadabad, Mona  ( UCSF , San Francisco , California , United States )
  • Yedavalli, Vivek  ( Johns Hopkins School of Medicine , Baltimore , Maryland , United States )
  • Wade, Smith  ( University of California San Francisco , San Francisco , California , United States )
  • Kim, Anthony  ( UCSF , San Francisco , California , United States )
  • Halabi, Cathra  ( University of California San Francisco , San Francisco , California , United States )
  • Savastano, Luis  ( UCSF , San Francisco , California , United States )
  • Cooke, Daniel  ( UCSF , San Francisco , California , United States )
  • Hetts, Steven  ( UCSF , San Francisco , California , United States )
  • Amans, Matthew  ( UCSF , San Francisco , California , United States )
  • Narsinh, Kazim  ( University of California San Francisco , San Francisco , California , United States )
  • Josephson, Andy  ( UCSF , San Francisco , California , United States )
  • Metanat, Pouya  ( UCSF , San Francisco , California , United States )
  • Hess, Christopher  ( UCSF , San Francisco , California , United States )
  • Nael, Kambiz  ( UCSF , San Francisco , California , United States )
  • Tavakkol, Elham  ( UCLA , Los Angeles , California , United States )
  • Ismail, Ameera  ( UCLA , Los Angeles , California , United States )
  • Bahr-hosseini, Mersedeh  ( UCLA , Los Angeles , California , United States )
  • Szeder, Viktor  ( UCLA , Los Angeles , California , United States )
  • Colby, Geoffrey  ( UCLA Neurosurgery , Los Angeles , California , United States )
  • Saver, Jeffrey  ( GEFFEN SCHOOL OF MEDICINE AT UCLA , Los Angeles , California , United States )
  • Liebeskind, David  ( UCLA , Los Angeles , California , United States )
  • Author Disclosures:
    Mona Asghariahmadabad: DO NOT have relevant financial relationships | Vivek Yedavalli: DO have relevant financial relationships ; Consultant:RAPIDAI Ischemaview (Menlo Park, CA, USA):Active (exists now) | Smith Wade: No Answer | Anthony Kim: DO NOT have relevant financial relationships | Cathra Halabi: DO NOT have relevant financial relationships | Luis Savastano: DO NOT have relevant financial relationships | Daniel Cooke: DO NOT have relevant financial relationships | Steven Hetts: DO NOT have relevant financial relationships | Matthew Amans: DO have relevant financial relationships ; Consultant:Stryker:Active (exists now) ; Individual Stocks/Stock Options:Mind Rhythm:Active (exists now) ; Research Funding (PI or named investigator):DOD:Active (exists now) ; Research Funding (PI or named investigator):NIH:Past (completed) ; Research Funding (PI or named investigator):VS3 Medical:Active (exists now) ; Individual Stocks/Stock Options:VS3 Medical:Active (exists now) | Kazim Narsinh: No Answer | Andy Josephson: No Answer | Pouya Metanat: DO NOT have relevant financial relationships | Christopher Hess: DO NOT have relevant financial relationships | Kambiz Nael: DO have relevant financial relationships ; Consultant:Olea Medical:Active (exists now) ; Consultant:Brainomix:Active (exists now) | Elham Tavakkol: DO NOT have relevant financial relationships | Ameera Ismail: No Answer | Mersedeh Bahr-Hosseini: DO NOT have relevant financial relationships | Viktor Szeder: No Answer | Geoffrey Colby: DO have relevant financial relationships ; Consultant:Stryker Neurovascular:Active (exists now) ; Consultant:Nuvascular:Active (exists now) ; Consultant:Cerenovus:Active (exists now) ; Consultant:Rapid Medical:Active (exists now) ; Consultant:MicroVention:Active (exists now) ; Consultant:Medtronic:Active (exists now) | Jeffrey Saver: DO have relevant financial relationships ; Consultant:Abbott:Active (exists now) ; Individual Stocks/Stock Options:Viz.ai:Active (exists now) ; Individual Stocks/Stock Options:Let's Get Proof:Active (exists now) ; Individual Stocks/Stock Options:Neuronics:Active (exists now) ; Consultant:Genentech:Expected (by end of conference) ; Consultant:Roche:Active (exists now) ; Consultant:Novo Nordisc:Active (exists now) ; Consultant:AstraZeneca:Active (exists now) ; Consultant:BrainQ:Active (exists now) ; Consultant:Medtronic:Active (exists now) | David Liebeskind: DO NOT have relevant financial relationships
Meeting Info:
Session Info:

Imaging Moderated Poster Tour I

Wednesday, 02/05/2025 , 06:00PM - 07:00PM

Moderated Poster Abstract Session

More abstracts on this topic:
More abstracts from these authors:
Aneurysm neck width reduces flow diversion in new generation stent placed at high curvature ICA segment

Chien Aichi, Szeder Viktor, Boyle Noel, Colby Geoffrey, Duckwiler Gary

A cerebrovascular longitudinal atlas: different rates of morphological change in aneurysm patients associated with hypertension and diabetes

Chien Aichi, Salamon Noriko, Vinuela Fernando, Szeder Viktor, Colby Geoffrey, Jahan Reza, Boyle Noel, Villablanca Juan, Duckwiler Gary

You have to be authorized to contact abstract author. Please, Login
Not Available

Readers' Comments

We encourage you to enter the discussion by posting your comments and questions below.

Presenters will be notified of your post so that they can respond as appropriate.

This discussion platform is provided to foster engagement, and simulate conversation and knowledge sharing.

 

You have to be authorized to post a comment. Please, Login or Signup.


   Rate this abstract  (Maximum characters: 500)